Stemline Therapeutics (NASDAQ:STML)

CAPS Rating: 3 out of 5

Results 1 - 1 of 1


Member Avatar zzlangerhans (99.78) Submitted: 12/15/2013 10:57:02 AM : Outperform Start Price: $20.32 STML Score: -82.80

No stock better exemplifies the summer 2013 biopharma IPO bubble than Stemline. The stock peaked closed to 50 in October despite a lack of significant catalysts and has plunged along with the other 2013 IPO's. The current cap of 250M is much more attractive for a narrowly focused biopharma headed into pivotal trials of a largely unproven therapy for a potentially lucrative indication. Lock-up expiration activity is likely resolved and hedge fund transactions have lately been favorable. If the momentum reverses once the pivotal trials kick off in early 2014, I might tag a small chunk of speculative capital onto Stemline for the ride.

Results 1 - 1 of 1

Featured Broker Partners